We are pleased to announced two of our Q2 company picks for 2017: Paratek Pharmaceuticals (PRTK) and Selecta Biosciences (SELB) . Our followers are aware that we started positions in our hypothetical fund for PRTK on Feb 28 and SELB on March 2. Since then we have been steadily increasing our positions and are currently up +24.21% with PRTK and +7.14% with SELB.
Read our exclusive research reports for our first two Q2 2017 picks below and stay tuned for more of our Q2 picks:
Best,
AMP Biotech Team